- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
Patent holdings for IPC class A61P 7/04
Total number of patents in this class: 1747
10-year publication summary
|
34
|
37
|
79
|
109
|
93
|
136
|
116
|
151
|
123
|
100
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 214 |
56 |
| Chugai Seiyaku Kabushiki Kaisha | 1372 |
29 |
| Cellphire, Inc. | 116 |
28 |
| The Children's Hospital of Philadelphia | 801 |
25 |
| Takeda Pharmaceutical Company Limited | 2706 |
24 |
| Genzyme Corporation | 1297 |
23 |
| Novo Nordisk A/S | 2279 |
20 |
| Laboratoire Francais du Fractionnement et des Biotechnologies | 293 |
17 |
| CSL Behring Lengnau AG | 126 |
17 |
| Baxter International Inc. | 2417 |
16 |
| Novo Nordisk Health Care AG | 336 |
16 |
| Baxter Healthcare S.A. | 1838 |
15 |
| Pfizer Inc. | 3391 |
13 |
| Cantab Biopharmaceuticals Patents Limited | 23 |
13 |
| Baxalta Incorporated | 304 |
12 |
| The University of North Carolina at Chapel Hill | 2058 |
12 |
| CSL Behring GmbH | 343 |
11 |
| Osaka University | 3394 |
11 |
| The General Hospital Corporation | 4781 |
10 |
| CSL Limited | 254 |
10 |
| Other owners | 1369 |